StemCell Therapy

October 22, 2021

About 12 years ago in Russia, wildlife conservation biologist Adam Stein was involved with projects on the Oriental stork.

A Russian colleague had been working on how to save the species then numbering only about 3,000 throughout its entire habitat from Siberia down into Manchuria, Korea and Japan. Stein observed firsthand the experience of working across borders and languages, and dealing with capacity issues and proprietary data to save a species that now numbers about 7,000.

Now, during a time where many things have changed, Stein has taken the international conservation biology class offered at Arizona State Universitys College of Integrative Sciences and Arts from classroom lectures to weekly meetings with researchers from Siberia to the Solomon Islands, Nicaragua and Tanzania.

It's been a great opportunity for the students just to really see how these different cultures work, to get conversations with those people on the ground, Stein said.

The combination of being isolated with new meeting technology offered a fresh opportunity to recast the class.

We can't necessarily go to the Solomons for the week or to Tanzania for the week, Stein said. And we can't cram all that into the semester. And so what better way than to just take this technology and say, this is the best way to teach this class instead of having a Westerner sit up here and talk about, you know, this is how it goes.

The course has been offered at ASU for some time, but its the first time Stein has taught it. Students learn about wildlife around the world, including biogeography, biodiversity, conservation topics and the complexity of conserving wildlife in both developed and developing nations.

Stein has traveled around the world as a conservation biologist and met scores of people in the field.

I've met a lot of different individuals at different levels of conservation and have been able to see ecosystems and conservation issues firsthand, he said. And when I was offered to teach this course, I said, this is a great opportunity for me to touch base with all of these colleagues from around the world. And instead of me telling the story that I've witnessed, have them firsthand tell these stories and tie it into an overall picture of how conservation works on an international level.

Conservation biology is a rigorous science that looks at what is needed to maintain populations. What is the amount of species needed for enough genetic variability? How do we maintain that population? How do we keep that minimal viable population going? What's the dynamic area that's needed to support those organisms working within the matrix of human interactions? The international component talks about why its a global problem.

Stein kicked off the semester with locals who live on the edge of one of the last large wildernesses in Central America in Nicaragua, a 2,500-square-kilometer ecosystem home to the last big populations of jaguars and other large mammals. Its vastly important for the connectivity of wildlife species that make their way from Mexico through to South America. Without that linkage, two continents are broken apart.

It has ramifications beyond just its own borders about the connectivity of these ecosystems, and it's under threat, Stein said. We see that it's being undermined in the last five to 10 years. It's being degraded by deforestation, by intruders into this environment. And Nicaragua is a very poor country and doesn't invest a lot of resources into this conservation."

Initially people might assume these intruders are impoverished residents looking for opportunities, Stein said but in fact, there are reports that the government is the driver behind it, seizing land and giving concessions to companies such as large cattle operations.

"What I think it did for the students was it kind of opened their eyes to the government may be the problem here, and why can't the people do something about that?" he said.

"These are the questions that are generated by the students ... and the feedback I've heard has really, you know, shown the complicated issues that come with that."

Top photo of Nicaragua courtesy of Pixabay.com

See the original post here:
How mindfulness-based stress reduction can improve quality of life in people with autism - ASU News Now

The COVID-19 outbreak and subsequent lockdowns and pandemic situation changed the way of handling clinical trials. This greatly affected the U. K. pharmacovigilance market. Furthermore, rising externalization as well as outsourcing of clinical trials by several biotechnological as well as pharmaceutical companies is boosting the demand in U. K. pharmacovigilance market. Some other factors driving the growth in the U. K. pharmacovigilance market include presence of regulatory mandates prescribing ideal trial conduct as well as pointing out strict post-marketing vigilance.

The study on the U. K. pharmacovigilance market offers a critical assessment of key growth dynamics, technology trends, regulatory frameworks prevailing in key regional markets, and recent investment trends among prominent stakeholders. The research provides a detailed insight into the share and size of various segments in the U. K. pharmacovigilance market. The report also estimates their projected valuation by the end of 2031, and regulations that may disrupt or hold game-changing potential in the near future.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=7711

The U.K. Pharmacovigilance Market: Major Trends and Drivers

Increasing incidence of adverse drug reactions or ADRs caused by drug abuse as well as rising prevalence of severe diseases that require combination drug therapies are two of the major drivers for the products in the U. K. pharmacovigilance market. Furthermore, rising efforts in increasing the production of essential drugs as well as presence of strict government norms and regulatory frameworks may fuel the growth in the U. K. pharmacovigilance market in coming years. Similarly, advancements in creation of ADR databases as well as rising usage of medical information systems are also expected to bolster the upward trajectory of the U. K. pharmacovigilance market in near future.

The government of the United Kingdom has integrated several new and cutting edge technologies such as virtual trial technology, to supplement the processing of negative events pertaining to the COVID-19 vaccines. Integration of virtual trial technology is vaccine development as well as in securing full service COVID trials as well as studies is also bolstering the development in U. K. pharmacovigilance market. Furthermore, rising drug development efforts in the field such as personalized medicine, orphan drugs, adaptive trial designs, biosimilars, and companion diagnostics is also expected to foster the demand in the U. K. pharmacovigilance market in near future.

The U.K. Pharmacovigilance Market: Key Players and Manufacturers

The research report features a thorough evaluation of the competitive landscape in U. K. pharmacovigilance market. It includes information about the major players in the market. The business intelligence report highlights their product range, production volume, market share and size, profile, key competitors, and regions of operations. Through assessment of historic data about pricing and profit margins, readers can gauge potential opportunities in various segments in the U. K. pharmacovigilance market.

Get Table of Content of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=7711

Some of the key and leading players as well as manufacturers operating within the U. K. pharmacovigilance market may include Accenture, IBM Corporation, ICON PLC, IQVIA, PAREXEL International Corporation, Cognizant, ArisGlobal, Capgemini, TAKE Solutions Ltd., and BioClinica, among others. The U. K. pharmacovigilance market is considered to be somewhat fragmented owing to the presence of significant number of players operating within the industry. Some of the key strategies adopted by the players in the U. K. pharmacovigilance market for expansion include constant product development, partnerships, alliances, and collaborations, among others.

For example, Ashfield Pharmacovigilance Inc., a United States based subsidiary of UDG Healthcare PLC, was acquired by the Ergomed PLC for complete cash consideration of US$ 10 million. This acquisition is aimed at supplementing the development of Ergomed PLLCs combined PV as well as CRO business all over the world. This will also aid them in establishing presence and offering avenues for potential growth in the U. K. pharmacovigilance market in North America.

Get Discount on the Latest Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=7711

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

Rohit Bhisey

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

Excerpt from:
UK Pharmacovigilance Market | Rising Usage of Medical Information Systems Drive the Industry Growth - BioSpace

Preventive medicine is a specialty that bridges clinical practice and public health. Specialists work in diverse settings and tap into a broad skill set to prevent disease and promote the health of individuals, communities and populations.

Physicians completing a preventive medicine residency gain a breadth of skills that opens many potential career paths in population health system management, public health and epidemiology, clinical care, health informatics, public health policy development and much more. Preventive medicine physicians work in a variety of settings including state and local health departments, Fortune 100 companies, health systems and all levels of government.

Click HERE to download a full list of Preventive Medicine Residency Programs.

Completion of residency training in preventive medicine is an essential step to become certified in one or more of the preventive medicine specialty areas: Public Health and General Preventive Medicine, Occupational Medicine, and Aerospace Medicine.

There are currently 72accredited preventive medicine residency training programs in the United States. Programs are administered by schools of medicine, schools of public health, state or local health departments, or in federal government agencies or branches of the uniformed services. They take an individualized approach to training, with approximately 350 residents in training every year.

Residency program accreditation and ongoing compliance reviews are performed by the Preventive Medicine Residency Review Committee of the Accreditation Council for Graduate Medical Education (ACGME).

Prospective residents must contact their desired residency programs directly for information and application instructions. Program directors may connect residents with program match specialists who can provide additional information and guidance. Many programs participate in the Preventive Medicine Electronic Residency Application Service.

ACPM administers a voluntary standardized acceptance process for General Preventive Medicine and Public Health residency programs. This centralized service provides the participating programs with a uniform method of selecting residents. ACPM opens registration in October and application review begins the following January.

Prior to an appointment in a preventive medicine residency program, applicants must have successfully completed at least 12 months of clinical education in a residency program accredited by the ACGME, Royal College of Physicians and Surgeons of Canada, or the College of Family Physicians of Canada.

Experience must include at least 11 months of direct patient care, in both inpatient and outpatient settings, where residents developed competency in the following clinical skills:

In addition to the base skills related to clinical practice, preventive medicine residency programs feature competencies in the following areas:

Two-year training programs include didactics, clinical training, research, public health and other population-based experiences. The didactic training includes both residency-lead seminars, as well as the acquisition of a Master in Public Health or equivalent degree. Those residents entering with an appropriate degree can enhance their didactics with additional coursework. Whether through a Master in Public Health or other equivalent degree, all residents must complete graduate level courses in epidemiology, biostatistics, health services management and administration, environmental health and the behavioral aspects of health.

Practicum experiences can take place across the two years of the residency and include acquisition of skills in clinical and population prevention medicine. Examples of practicum experiences include appointments in: local, state and federal health departments; health maintenance organizations; peer review organizations; community and migrant health centers; occupational health clinics; industrial sites; regulatory agencies; NASA; OSHA; research settings and many more. Reference the Examples of Preventive Medicine Training Opportunities for a comprehensive listing.

Combined residency training is designed to lead to board certification in two medical specialties. Combined programs may reduce the overall length of required training by as much as one year. Residencies that offer combined training programs must maintain their accreditation status through each specialty Residency Review Committee.

The ABPM and the American Board of Internal Medicine have formal guidelines for a combined 4-year residency training program, which leads to board certification in both Preventive Medicine and Internal Medicine.

Several institutions also offer 4-year programs with combined training in preventive medicine and family medicine.

The preventive medicine Standardized Acceptance Process (SAP) is a service offered by ACPM to aid in matching prospective preventive medicine residents with available positions at residency programs across the country. The SAP helps to create homogeneity in residency program acceptance timetables, and ensures programs and candidates have adequate time to complete interviews and make and accept offers.Since 2018, nearly three quarters of all General Preventive Medicine and Public Health residency programs have participated in the SAP match.

SAP policy information, program guidelinesand resources for 2022 will be posted soon.

October - November - Programs Register for the SAP

October- January, 2022 - Applicants Register for the SAP

November 12 - Program InformationalSession

November 19 - Applicant Informational Session

January 24 - 28,2022- Applicants submit ranked lists

February 1- 4,2022- Programs submit ranked lists

February 7 - 11, 2022 - SAP pairing period

Accordion toggle

Previous Slide

Next Slide

Accordion toggle

Previous Slide

Next Slide

Originally posted here:
Preventive Medicine Residency Programs | ACPM

Preventive medicine services, or well visits, are evaluation and management (E/M) services provided to a patient without a chief complaint. The reason for the visit is not an illness or injury (or signs or symptoms of an illness or injury), but rather to evaluate the patients overall health, and to identify potential health problems before they manifest.The CPT code book includes a dedicated set of codes to describe preventive medicine services:

99381 Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; infant (age younger than 1 year)99382 early childhood (age 1 through 4 years)99383 late childhood (age 5 through 11 years)99384 adolescent (age 12 through 17 years)99385 18-39 years99386 40-64 years99387 65 years and older99391 Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year)99392 early childhood (age 1 through 4 years)99393 late childhood (age 5 through 11 years)99394 adolescent (age 12 through 17 years)99395 18-39 years99396 40-64 years99397 65 years and older

Code assignment is determined by the patients age (as detailed in the code descriptor), and whether the patient is new (99381-99387) or established (99391-99397). CPT applies the three year rule to determine new vs. established status. A patient is established if any physician in a group practice (or, more precisely, any physician of the same specialty billing under the same group number) has seen that patient for a face-to-face service within the past 36 months. The Decision Tree for New Vs Established Patients in the Evaluation and Management Services Guidelinesportion of the CPT code book can help you to select the appropriate patient status.Service Content Varies by Patient CircumstancePreventive medicine services must include a comprehensive history and examination, and age-appropriate anticipatory guidance. In the context of preventive medicine services 99381-99397, a comprehensive exam is not the comprehensive exam as defined by either the 1995 or 1997 Evaluation and Management Documentation Guidelines. Instead, the exam should reflect an appropriate assessment, given the specific patients age and sex. For example, the specifics of the exam will differ for a 4-yr-old male and a 22-year-old female.Services for a young child will assess physical growth (height, weight, head circumference) and developmental milestones such as speech, crawling, and sleeping habits. Anticipatory guidance may include use of car seats and other safety issues, introducing new foods, etc.An adolescent preventive service may include scoliosis screening, assessment of growth and development, and a review of immunizations. Anticipatory guidance may focus on developing positive health habits and self-care, including discussion of drug, alcohol, and tobacco use, and sexual activity.A comprehensive preventive visit for an adult female patient will include a gynecologic examination, Pap smear, and breast exam. An adult males exam would include an examination of the scrotum, testes, penis, and the prostate for older patients. Anticipatory guidance may focus on issues of health maintenance, such as alcohol and tobacco use, safe sex practices, nutrition, and exercise. The patients employment status and other family issues may be discussed. As patient age advances, cholesterol levels, blood sugar, and prostate-specific antigen(PSA) testing may become increasingly relevant.Diagnoses Must Support Preventive Nature of the VisitEvery billed service must be supported by an ICD-10-CM code(s) that describe the reason for that service. In the case of a well visitbecause there is no patient complaintyou should turn to so-called Z codes (Factors influencing health status and contact with health services). For example:

Z00.110 Health examination for newborn under 8 days oldZ00.111Health examination for newborn 8 to 28 days oldZ00.121 Encounter for routine child health examination with abnormal findingsZ00.129Encounter for routine child health examination without abnormal findingsZ00.00 Encounter for general adult medical examination without abnormal findingsZ00.01 Encounter for general adult medical examination with abnormal findingsZ01.411 Encounter for gynecological examination (general) (routine) with abnormal findingsZ01.419 Encounter for gynecological examination (general) (routine) without abnormal findings

You also should code for any abnormalities found, regardless of whether the finding requires an additionally reported service.Testing and Problem-Focused Testing Are SeparatePer CPT coding guidelines:If an abnormality is encountered or a preexisting problem is addressed in the process of performing this preventive medicine evaluation and management service, and if the problem or abnormality is significant enough to require additional work to perform the key components of a problem-oriented E/M service, then the appropriate Office/Outpatient code 99201-99215 should also be reported. Modifier 25 should be added to the office/outpatient code to indicate that a significant, separately identifiable evaluation and management service was provided on the same day as the preventive medicine service.To determine whether a problem requires significant work, consider whether the available documentation is sufficient to support each service (the preventive service and the problem-oriented service), separately.Additionally, per CPT coding guidelines, as supported by CPT Assistant(April 2005):

The codes in the preventive medicine services include the ordering of appropriate immunization(s) and laboratory or diagnostic procedures. The performance of immunization and ancillary studies involving laboratory, radiology, other procedures, or screening tests identified with a specific CPT code are reported separately.

Payer Coverage May VaryThe Affordable Care Act (ACA) requires insurers to cover recommended preventive services without any patient cost-sharing, but exact coverage and reporting requirements may vary from payer to payer. As CPT Assistant(April 2005) notes:

Codes 99381-99397 are used to report the preventive evaluation and management (E/M) of infants, children, adolescents, and adults. The extent and focus of the services will largely depend on the age of the patient. For example, E/M preventive services for a 28-year-old adult female may include a pelvic examination including obtaining a pap smear, breast examination, and blood pressure check. Counseling is provided regarding diet and exercise, substance use, and sexual activity.

Based upon this information, it is not be appropriate to separately report for a pelvic exam including obtaining of the pap smear, nor the breast exam as these services are considered part of a comprehensive preventive medicine E/M services.Although this reporting method reflects the intent of CPT coding guidelines, third-party payers may request that preventive medicine services be reported differently. Third-party payers should be contacted for their specific reporting guidelines.Authors Note:Although the CPT Assistantarticle cited pre-dates the ACA, the advice to contact your payers regarding their reporting requirements remains valid.Be aware, as well, that Medicare reporting requirements, as stipulated by the Centers for Medicare & Medicaid Services (CMS) often differ from CPT guidelines. For more information about Medicare Preventive Medicine Services and Screenings, visit the CMS website.

John Verhovshek, MA, CPC, is a contributing editor at AAPC. He has been covering medical coding and billing, healthcare policy, and the business of medicine since 1999. He is an alumnus of York College of Pennsylvania and Clemson University.

See the rest here:
Preventive Medicine Services Reporting - AAPC Knowledge Center

Scope & Importance

Vision

We work hard to improve the lives of our patients and their families by collaborating with the healthcare community. We offer clinical experience to both allied health professionals and patients.

We focus on the right to comprehensive, high-quality primary care for individuals and populations.

To provide the most safest, ethical, and effective medical care possible. Practice the safest, most ethical and effective medical care possible. Breakthrough research can lead to the discovery of new treatments and therapies. Promoting healthy and reducing health disparities. Educate and inspire faculty, healthcare developers, policy makers and leaders of the next generation. Build a philanthropic culture for patient care and research.

Mission

Our objective is to disseminate healthcare information and innovations that will guide in a new era of medicine.

Healthcare Market Forecast

Healthcare is one of those industries that has never seen ups and downs, particularly since technology has taken over its progress.Even throughout the pandemic, technology was important in advancing healthcare to a higher level.

In 2019, the global home healthcare market was valued at USD 281.8 billion, with a compound annual growth rate (CAGR) of 7.9% predicted from 2020 to 2027. Market growth is expected to be increased by global population ageing and rising patient preference for value-based healthcare. In 2019, the World Health Organization (WHO) estimated that 703 million people aged 65 and up lived in the world. By 2050, the number of elderly people is expected to increase to 1.5 billion. The ageing population necessitates more patient-centric healthcare services, which in turn raises demand for healthcare personnel and agencies, drive market growth.

Medicare is the largest single payer of home healthcare services in the United States. Medicare accounts for more than 40% of all home health care expenses.

Healthcare Market Overview in USA

The home healthcare market is divided into two components: equipment and services, wherein the services segment dominated the market with a share of 80% in 2019. The demand for home healthcare agencies is increasing as the world's population ages, resulting in better patient outcomes. Furthermore, the rising frequency of chronic diseases among the elderly is a prominent factor contributing to market growth.

In 2019, therapeutic devices dominated the equipment market. The growing number of patients with chronic or severe respiratory infections, urinary infections, or end-stage renal disease (ESRD) necessitates the use of innovative devices for treatment. Another important element driving the therapeutic equipment market is lower service rates for in-home healthcare when compared to hospitals or nursing homes. End-stage renal diseases (ESRD) affects roughly 750,000 persons in the United States each year, and 2 million patients worldwide, according to the University of California, San Francisco

The diagnostics equipment market is expected to develop at a healthy rate over the projected period, owing to the rising prevalence of diabetes and cardiovascular illnesses, both of which necessitate constant monitoring. Furthermore, increasing patient awareness of the screening process and technological advancements, such as the integration of microfluidics, sensors, the Internet of Things (IoT), smartphones, and wearables, provide point-of-care testing to patients and represent a significant opportunity for providing sensitive, low-cost, rapid, and connected diagnostics.

In 2019, North America dominated the home healthcare industry with a 42% share. In 2019, the United States had the greatest market share in North America, due to changing trends towards in-home healthcare from nursing homes, technology advancements, and the presence of modern medical infrastructure. In addition, the region's market is being driven by high patient awareness levels, rising healthcare expenses, and the deployment of a streamlined regulatory framework. Profits in the U.S. healthcare industry are expected to grow at a 5% annual rate through 2024, with medtech and healthcare IT experiencing the fastest growth. Profits in healthcare information technology are expected to rise from 14 billion US dollars in 2019 to 28 billion US dollars in 2024.

Healthcare Market Overview in Japan

Japan is the world's second-largest market for medical devices and healthcare. Japan is open to innovative and high-quality products and technologies, with nearly 45% of medical devices imported.

By nearly 180,000 medical facilities, including hospitals and clinics, Japan has the world's second largest healthcare market. In fiscal FY 2010, national medical expenditure was 37.4 trillion (approx 249 billion @150 = 1), a 3.9 percent increase over the previous year. This was a record-high in terms of both level and rate of growth, driven by the implementation of cutting-edge medical technologies as well as one of the world's fastest ageing populations. As a result of the ageing population, demand for assistive and care products has increased. However, the market is already crowded with a wide range of products, making it extremely difficult for new entrants lacking unique selling points.

The Japanese medical device market is also the world's second largest, valued at 2.4 trillion yen (approx. 16 billion) in 2011, with foreign manufacturers accounting for 44.4 percent of the products. Japan has long been known as a high-tech nation, but the market for medical devices is still heavily reliant on imports.

Healthcare Market Overview in Europe

Despite rising global trade tensions and a sluggish global economic outlook for 2020, the global healthcare market is expected to surpass $2 trillion in 2020. BREXIT is expected to have a significant impact on the United Kingdom, Europe's largest digital healthcare market.

In the forecast period of 2020 to 2027, the healthcare IT market is expected to grow. According to Data Bridge Market Research, the market will be worth USD 150.97 billion by 2027, growing at a CAGR of 15.62 percent during the forecast period.

The European healthcare market is expected to grow from approximately $2080 billion in 2016 to approximately $2125 billion in 2020. The European healthcare market is expected to exceed US$ 224 billion by 2022.

The European home healthcare market was worth USD 70.28 billion in 2019 and is expected to grow at an 8.37 percent CAGR to reach USD 105.04 billion by 2024.

In 2019, Germany had the highest market share in Europe, followed by France. This is mostly due to rising in-home healthcare spending in the country and rising demand for the skilled nursing workers to provide in-home care.

Healthcare Market Overview in Australia

The health care and social assistance industry is Australia's largest employer. This industry employed over 1.7 million people in 2020, with a projected increase to more than 1.9 million by 2024.

Occupations related to the HLT Health Training Package account for roughly one-third of the workforce in Health Care and Social Assistance. The occupations with the highest proportion of the workforce are Aged and Disabled Carers and Nursing Support and Personal Care Workers. Both are expected to grow significantly until 2024, with Aged and Disabled Carers growing by more than 25%. Other occupations in this sector are expected to grow to varying degrees as well. Welfare Support Workers, for example, are expected to grow by nearly 23%, Health and Welfare Services Managers by about 19%, and Complementary Health Therapists by about 15%.

Medical device industry overview: The medical device sector in Australia is mature, with a well-developed regulatory system. However, in the next years, it will be one of the slowest-growing economies in the South Pacific area. In 2016, the market was worth $4 billion, down from $5 billion in 2014. Due to Australia's sinking currency, market recovery will be delayed in 2019. Despite its low growth, Australia's ageing population, Federal Budget measures, and openness to adopt new technology should help to stabilise the market.

Australian market opportunities: Australia's healthcare business is sophisticated and open to innovative products. A wide range of medical gadgets, particularly those designed to treat and manage age-related disorders, are in high demand. Because the Australian market is pushed to cut prices, imported devices are frequently inventive and cost-effective. In addition, there is a growing demand for gadgets that help people with disabilities and chronic pain, as well as those that help them recover faster. The Australian market is highly accessible from a regulatory aspect for items that already have CE Marking.

Healthcare Market Overview in Middle East

Healthcare prospects are expanding across the Middle East. According to a recent analysis by the US-UAE Business Council, healthcare spending in the UAE is forecast to rise from $17 billion in 2017 to $21.3 billion by 2021, with a CAGR of 8.5 percent predicted between 2018 and 2023 in the UAE Healthcare Sector Outlook 2023 report.

Aging populations, longer life expectancies, and sedentary lifestyles, all of which contribute to an increase in obesity, cancer, and diabetes, are driving demand growth. New modes of care and out-of-hospital services are emerging as a result of an emphasis on prevention and well-being rather than simply treating patients. Saudi Arabia, for example, is developing a new healthcare system that includes primary, community, and secondary care.

Simultaneously, labour challenges, such as a lack of competent clinical staff and a strong reliance on expatriates, are pushing demand for technology such as digital health, artificial intelligence, and robots to fill the gap. By 2025, the region's medical technology market is estimated to be worth $31.6 billion.

The size of the Middle East and Africa Home Healthcare Market was worth USD 21.62 billion in 2020 and estimated to be growing at a CAGR of 9.30%, to reach USD 33.32 billion by 2025 during the forecast period.

These countries are expected to have a market size of USD 102 billion in 2024 with a CAGR value of 9.2% during the forecast period. Healthcare is the fastest-growing sector in the UAE, accounting for 79% of the market.

Healthcare Market Overview in APAC

The size of the home Healthcare Market in the Asia Pacific was worth USD 43.25 billion in 2020 and estimated to be growing at a CAGR of 12.56% to each USD 78.14 billion by 2025.

Home Healthcare Market Report Scope

Report Attribute

Details

Market size value in 2020

USD 303.6 billion in 2020

Revenue forecast in 2027

USD 515.6 billion

Growth Rate

CAGR of 7.9% from 2020 to 2027

Max Seats15 seats

Speaker Time20 mins

Go here to read the rest:
Healthcare Conferences and Preventive Medicine Conferences ...

Low-dose aspirin or baby aspirin (81 to 100 milligrams) has been used as a safe and cheap way to reduce the risk of cardiovascular diseases, heart attacks, strokes, and blood clots. Aspirin does this by thinning out the blood and preventing blood clots from forming, which may block arteries. Getty images

The United StatesPreventive Services Task Force (USPTF) released adraft guidelineon October 12 stating that a daily regimen of low-dose aspirin is no longer recommended as a preventative measure to reduce the risk of cardiovascular problems in older adults without heart disease, reports Lindsey Tanner for theAssociated Press.

Individuals over 60 should not take preventive aspirin because of the age-related risk for life-threatening bleeding. The guidelines are not yet final but may affect tens of millions of adults at high risk for cardiovascular disease, reports Roni Caryn Rabin for theNew York Times.

Ultimately, those currently on a low-dose aspirin regimen or who have cardiovascular risk factors should talk to their doctors about what is best for them.

We dont recommend anyone stop without talking to a clinician, and definitely not if they have already had a heart attack or stroke, says Chien-Wen Tseng, a USPTF memberand a University of Hawaii research director, to theNew York Times.

The report also states that those aged between 40 and 60 and worried about their heart health should decide to take aspirin on a case-by-case basis, reports Ed Cara forGizmodo.

The panel consists of 16 medicine and disease prevention experts who evaluate evidence-based preventative measures and screening tests. Panel members are appointed by theAgency for Healthcare Research and Quality.

Low-dose aspirin or baby aspirin (81 to 100 milligrams) has previously been recommended as a safe and cheap way to reduce the risk of cardiovascular diseases, heart attacks, strokes, and blood clots. Aspirin does this by thinning out the blood and preventing blood clots from forming, per theNew York Times. The drugseems to most help individuals who already have, or are at a high riskfor, cardiovascular disease.The panel found some evidence that baby aspirin may only benefit people between 40 and 60 years of age who have a 10 percent risk of having a heart attack or stroke, per the Associated Press.

However, aspirin can also cause life-threatening bleeding inthe digestive tractor brain, per the New York Times. One study published in 2018 in theNew England Journal of Medicinefound that the risk of bleeding from an aspirin regimen outweighs its potentialbenefits for those over 70 years of age,Gizmodoreports.

The USPTF made their assessments based on a literature review of data from recent trials and population studies.For older people who have no risks of heart disease, the potential for bleeding damageoutweighs any aspirin benefits.

When we looked at the literature, most of it suggested the net balance is not favorable for most people there was more bleeding than heart attacks prevented, says Amit Khera, an author of the guideline, to theNew York Times. And this isnt nose bleeds, this can be bleeding in the brain.

The draft recommendation statement is currently open for public comment until November 8, before a final version of the report Is published, theNew York Timesreports.

Theres no longer a blanket statement that everybody whos at increased risk for heart disease, even though they never had a heart attack, should be on aspirin, Tseng explains to theNew York Times. We need to be smarter at matching primary prevention to the people who will benefit the most and have the least risk of harm.

Visit link:
Aspirin No Longer Recommended as a Preventative Measure Against Heart Attacks and Strokes in Older Individuals - Smithsonian

(Reuters) - Here's what you need to know about the coronavirus right now:

Merck seeks first U.S. FDA authorization for COVID-19 tablet

Merck & Co said on Monday it has applied for U.S. emergency use authorization for its tablet to treat mild-to-moderate patients of COVID-19, putting it on course to become the first oral antiviral medication for the disease.

Its authorization could help change clinical management of COVID-19 as the pill can be taken at home. The treatment, molnupiravir, could halve the chances of death or being hospitalized for those most at risk of contracting severe COVID-19, according to the drugmaker.

The interim efficacy data on the drug, which has been developed with Ridgeback Biotherapeutics, had heavily impacted the shares of COVID-19 vaccine makers when it was released last week.

AstraZeneca antibody cocktail succeeds in late-stage study

AstraZeneca's experimental COVID-19 drug has helped cut the risk of severe disease or death in a late-stage study, the British drugmaker said on Monday, a boost to its efforts to develop coronavirus medicines beyond vaccines.

The drug, a cocktail of two antibodies called AZD7442, reduced the risk of severe COVID-19 or death by 50% in non-hospitalised patients who have had symptoms for seven days or less, meeting the main goal of the study.

AstraZeneca's therapy, delivered via injection, is the first of its kind to show promise both as a preventative medicine and as a treatment for COVID-19 following multiple trials. It is designed to protect people who do not have a strong enough immune response to vaccines.

Sydney reopens as Australia looks to live with COVID-19

Sydney's cafes, gyms and restaurants welcomed back fully vaccinated customers on Monday after nearly four months of lockdown, as Australia aims to begin living with the coronavirus and gradually reopen with high rates of inoculation.

Some pubs in Sydney, Australia's largest city, opened at 12:01 a.m. (1301 GMT Sunday) and friends and families huddled together for a midnight beer.

Story continues

"I see it as a day of freedom, it's a freedom day," New South Wales state Premier Dominic Perrottet told reporters in Sydney, the state capital. "We are leading the nation out of this pandemic but this will be a challenge."

New Zealand makes vaccinations mandatory for health workers

New Zealand will require teachers and workers in the health and disability sectors to be fully vaccinated against COVID-19, Prime Minister Jacinda Ardern said on Monday, as she extended restrictions in Auckland, its largest city, for another week.

New Zealand is fighting the highly infectious Delta outbreak that forced it to abandon its long-standing strategy of eliminating the new coronavirus amid persistent infections.

"New Zealand is at one of the trickiest and most challenging moments in the COVID-19 pandemic so far," Ardern told reporters in Wellington. Ardern, however, said "there is a clear path forward" in the next few months to live with fewer curbs and more freedoms once the country reaches a higher level of vaccinations.

Russia's daily death toll hovers near all-time high

Russia reported 957 coronavirus-related deaths on Monday, close to the all-time high of 968 reported two days earlier.

The government coronavirus task force also said it had recorded 29,409 new cases in the last 24 hours, an increase from 28,647 cases on Sunday.

(Compiled by Linda Noakes; Editing by Alex Richardson)

Continued here:
What you need to know about the coronavirus right now - Yahoo News

The fate of the Biden administrations agenda on climate remains uncertain, captive to todays toxic atmosphere in Washington, DC. But the headlines of 2021 leave little in the way of ambiguity the era of dangerous climate change is already upon us, in the form of wildfires, hurricanes, droughts and flooding that have upended lives across America. A recent UN report on climate is clear these impacts will worsen in the coming two decades if we fail to halt the continued accumulation of greenhouse gases in the atmosphere.

To avert disaster, we must chart a different climate course, beginning this year, to achieve steep emissions reductions this decade. Meeting this moment demands an all hands-on-deck approach. And no stone should be left unturned in our quest for meaningful options for decarbonizing our economy.

But while it is tempting to pin our hopes on future technology that might reduce the scope of future climate damages, we must pursue such strategies based on sound science, with a keen eye for potential false leads and dead ends. And we must not allow ourselves to be distracted from the task at hand reducing fossil fuel emissions by technofixes that at best, may not pan out, and at worst, may open the door to potentially disastrous unintended consequences.

So-called geoengineering, the intentional manipulation of our planetary environment in a dubious effort to offset the warming from carbon pollution, is the poster child for such potentially dangerous gambits. As the threat of climate change becomes more apparent, an increasingly desperate public and the policymakers that represent them seem to be willing to entertain geoengineering schemes. And some prominent individuals, such as former Microsoft CEO Bill Gates, have been willing to use them to advocate for this risky path forward.

The New York Times recently injected momentum into the push for geoengineering strategies with a recent op-ed by Harvard scientist and geoengineering advocate David Keith. Keith argues that even in a world where emissions cuts are quick enough and large enough to limit warming to 1.5 degrees Celsius by 2050, we would face centuries of elevated atmospheric CO2 concentrations and global temperatures combined with rising sea levels.

The solution proposed by geoengineering proponents? A combination of slow but steady CO2 removal factories (including Keiths own for-profit company) and a quick-acting temperature fix likened to a band-aid delivered by a fleet of airplanes dumping vast quantities of chemicals into the upper atmosphere.

This latter scheme is sometimes called solar geoengineering or solar radiation management, but thats really a euphemism for efforts to inject potentially harmful chemicals into the stratosphere with potentially disastrous side effects, including more widespread drought, reduced agricultural productivity, and unpredictable shifts in regional climate patterns. Solar geoengineering does nothing to slow the pace of ocean acidification, which will increase with emissions.

On top of that is the risk of termination shock (a scenario in which we suffer the cumulative warming from decades of increasing emissions in a matter of several years, should we abruptly end solar geoengineering efforts). Herein lies the moral hazard of this scheme: It could well be used to justify delays in reducing carbon emissions, addicting human civilization writ large to these dangerous regular chemical injections into the atmosphere.

While this is the time to apply bold, creative thinking to accelerate progress toward climate stability, this is not the time to play fast and loose with the planet, in service of any agenda, be it political or scientific in nature. As the recent UN climate report makes clear, any emissions trajectory consistent with peak warming of 1.5 degrees Celsius by mid-century will pave the way for substantial drawdown of atmospheric CO2 thereafter. Such drawdown prevents further increases in surface temperatures once net emissions decline to zero, followed by global-scale cooling shortly after emissions go negative.

Natural carbon sinks over land as well as the ocean play a critical role in this scenario. They have sequestered half of our historic CO2 emissions, and are projected to continue to do so in coming decades. Their buffering capacity may be reduced with further warming, however, which is yet another reason to limit warming to 1.5 degrees Celsius this century. But if we are to achieve negative emissions this century manifest as steady reductions of atmospheric CO2 concentrations it will be because we reduce emissions below the level of uptake by natural carbon sinks. So, carbon removal technology trumpeted as a scalable solution to our emissions challenge is unlikely to make a meaningful dent in atmospheric CO2 concentrations.

As to the issue of climate reversibility, its nave to think that we could reverse nearly two centuries of cumulative emissions and associated warming in a matter of decades. Nonetheless, the latest science tells us that surface warming responds immediately to reductions in carbon emissions. Land responds the fastest, so we can expect a rapid halt to the worsening of heatwaves, droughts, wildfires and floods once we reach net-zero emissions. Climate impacts tied to the ocean, such as marine heat waves and hurricanes, would respond somewhat more slowly. And the polar ice sheets may continue to lose mass and contribute to sea-level rise for centuries, but coastal communities can more easily adapt to sea-level rise if warming is limited to 1.5 degrees Celsius.

While its appealing to think that a climate band-aid could protect us from the worst climate impacts, solar geoengineering is more like risky elective surgery than a preventative medicine. This supposed climate fix might very well be worse than the disease, drying the continents and reducing crop yields, and having potentially other unforeseen negative consequences. The notion that such an intervention might somehow aid the plight of the global poor seems misguided at best.

When considering how to advance climate justice in the world, it is critical to ask, Who wins and who loses? in a geoengineered future. If the winners are petrostates and large corporations who, if history is any guide, will likely be granted preferred access to the planetary thermostat, and the losers are the global poor who already suffer disproportionately from dirty fossil fuels and climate impacts then we might simply be adding insult to injury.

To be clear, the world should continue to invest in research and development of science and technology that might hasten societal decarbonization and climate stabilization, and eventually the return to a cooler climate. But those technologies must be measured, in both efficacy and safety, against the least risky and most surefire path to a net-zero world: the path from a fossil fuel-driven to a clean energy-driven society.

Kim Cobb is the director of the Global Change Program at the Georgia Institute of Technology and professor in the School of Earth and Atmospheric Sciences. She was a lead author on the recent UN Intergovernmental Panel on Climate Change (IPCC) Sixth Assessment Report. Follow her on Twitter: @coralsncaves

Michael E. Mann is distinguished professor of atmospheric science and director of the Earth System Science Center at Penn State University. He is author of the recently released book,The New Climate War: The Fight to Take Back our Planet. Follow him on Twitter:@MichaelEMann

See the original post:
Geoengineering: We should not play dice with the planet | TheHill - The Hill

When it comes to our health, just about everyone is looking for an extra boostparticularly during the COVID-19 pandemic. That desire has helped vitamins and supplements grow into a $150 billion worldwide industry. If you're considering taking a daily vitaminor are taking one nowit's important to know there are clear things vitamins can and can't do, as indicated by decades of research. And if you take them the wrong way, they can be harmful. Read on to find out what taking a daily vitamin does to your bodyand to ensure your health and the health of others, don't miss these Sure Signs You May Have Already Had COVID.

Woman taking her medication in her bedroom at home.

"If you're like everybody else in the world, and you don't eat a perfect diet every day, a multivitamin is going to fill in the little deficits you have on a daily basis," Kathryn Boling, MD, a family medicine doctor with Mercy Medical Center in Baltimore, told ETNT Health. "And if you're OK paying money for something that you're mostly going to pee out, but it's going to fill in those tiny little deficits, then take a multivitamin. I do."

RELATED: Health Habits You Should Avoid if Over 50

vitamin d

If your daily multivitamin contains vitamins C and D (and most do), those nutrients may support your immune system. "If you're deficient in vitamin D, that does have an impact on your susceptibility to infection," said Dr. Anthony Fauci, the nation's top infectious-disease specialist, in an interview last fall. "I would not mind recommendingand I do it myselftaking vitamin D supplements."

He added: "The other vitamin that people take is vitamin C because it's a good antioxidant, so if people want to take a gram or so of vitamin C, that would be fine."

RELATED: Everyday Habits That Add Years to Your Life, Say Experts

Story continues

Man sitting at the table and taking vitamin D

You might erase potential benefits from vitamins if you chase them with soda and sugary snacks, or use them as justification for too many cheat meals. "Supplements are never a substitute for a balanced, healthful diet," said Dr. JoAnn Manson, a preventative medicine specialist, in an interview with Harvard Health. "And they can be a distraction from healthy lifestyle practices that confer much greater benefits."

RELATED: Forgetting This One Thing Can Mean You Have Alzheimer's

young woman with stomach pain

If your vitamin contains high doses of certain nutrients, that can cause problems. Most vitamins are water-soluble, meaning they can't build up in the body because any excess is cleared by urine. But fat-soluble vitamins including A, D, E and K can build up in the body and may be dangerous at high levels, particularly A and E.

RELATED: Common Habits That Age You Faster, According to Science

Shot of woman nutritionist doctor writes the medical prescription for a correct diet on a desk with fruits, pills and supplements.

If you're taking multivitamins for protection against serious disease, you should know that the science isn't quite there yet. In 2018, researchers from Johns Hopkins analyzed studies involving almost half a million people; they determined that taking multivitamins doesn't lower your risk of heart disease, cancer, cognitive decline, or early death. Their advice: Don't waste your money on multivitaminsget the vitamins and minerals you need from food. And to get through this pandemic at your healthiest, don't miss these 35 Places You're Most Likely to Catch COVID.

Go here to read the rest:
What Taking a Vitamin Every Day Does to Your Body - Yahoo Lifestyle

If we have learned anything about controlling epidemics in the past year, its that its very difficult to halt the spread of disease with vaccines aloneespecially when they first appear. As the vaccines are endorsed, financed, and rolled out, other prevention strategies are key for controlling the illness.

Insecticide-treated bed netsthats what has made the biggest difference in most parts of Africa over the last couple of decades, Clarke said. And they will remain really important, because the insecticide on the bed net kills mosquitoes, and by reducing the number of mosquitoes, even people who dont sleep under the bed net will be protected, whereas a vaccine can only protect the person whos vaccinated.

Anotherstudy published last month found that combining vaccines with preventative drugs roughly doubled protection for kids. This combination can be used in places with clearly defined malaria seasons, particularly tied to the rainy season, where children are at very high risk of dying from the illness. Families were eager to get both the shots and the medications, Clarke said, because they take malaria extremely seriously.

Its imperative to move quickly, particularly when children are dying. Its all the question of investmentif the investment is made into these types of vaccines, it can be done in five years, Kappe said. When you look at, for example, the investments that have been made over a period of a year, a year and a half, in coronavirus vaccinesif the same resources would be thrown at malaria vaccines, I think we would be there already.

Read this article:
Welcome to the New Era of Vaccine Acceleration - The New Republic

[Left to Right] Clark Cahill, Manager of Events and Conferences at SCMP, Dr Ngai-tseung Cheung, Head of Information Technology & Health Informatics for the Hospital Authority, Megan Lam, Co-founder & CEO of Neurum Health, and Dr Matthew Man, Chief Executive Officer of Megasoft Limited took a deep dive into the current state of healthcare including the implementation of AI and the Internet of Things (IoT) into the industry in this series.

Dr Ngai-tseung Cheung, Head of Information Technology & Health Informatics for the Hospital Authority, mentioned how Covid-19 has made the close collaboration between the fields of healthcare, computer science, and machine learning even stronger.

Dr Matthew Man, Chief Executive Officer of Megasoft Limited, proposed the industry should start at the bottom [with] frontline staff [as they] have a lot of pain points.

Co-founder & CEO of Neurum Health, Megan Lam, said health and wellness is one size fits one as opposed to one size fits all.

(Left to Right) Joey Liu, Chief of Staff to the CEO at SCMP, and Dr Kee Yuan Ngiam, Group Chief Technology Officer at National University Health System, discussed how the end goal of medicine is to be more proactive and preventative rather than reactive.

Link:
Telehealth acts as a preview of the imminent digital revolution in healthcare as AI gains popularity - South China Morning Post

Dr. John McGonigle| Guest columnist

Dr. John McGonigle is an assistant clinical professor of family medicine at the Warren Alpert School of Medicine at Brown University.

I am a board-certified primary care doctor and an assistant clinical professor in family medicine at Brown University. I have been practicing primary care in Rhode Island since starting residency at Memorial Hospital in Pawtucket in 2006. I am educated, trained and schooled in the most powerful system of medicine the world has ever known.

Indeed, I have not infrequently described this system as analogous to the United States military. When Europe was overrun with Nazis, send the U.S. Army in, and tell them to flatten anything that resists. Its great for killing Nazis. As our recently concluded experience in Afghanistan tells us, send the military into a country and ask them to build schools and they will fail miserably. Wrong tool. Unbeatable in war, quiescent in peace.

The United States, Rhode Island, and the rest of the planet have been engaged in an undertaking unparalleled since the Second World War. While the politicians stay at home and dither over strategy, the people go offand fight. We have been asked to operate on a war footing, and whatever our political or social or economic means have enabled us to do we have done. We have cussed, and spit, and sometimes ridiculed higher officers but have done what they have asked, when they have asked, and in whatever spirits we can muster.

Last year was more straightforward in primary care, since it was all triage, all the time. We didnt know much about Sars-Co-V2, and knew less about treatment. Little of its spread, little of its contagion patterns. Our patients knew even less. They brought us unanswerable questions of life and death, and we worked tirelessly keeping the emergency rooms from being tragically overrun. The usual go to the ER for a full assessment when one was uncertain, or too tired to shake the uncertainty, was off limits.

To carry the battlefield the confusion had to be minimized. ER and ICU doctors and nurses fought heroically, in shifts. Primary Care is not adrenaline soaked and filled with mayhem, but it is unrelenting and remorseless. Primary Care makes it possible for ERs and ICUs to function at ALL times, and when Primary Care is overwhelmed like dishes piling up in the restaurant sink the establishment no longer functions anywhere near optimal efficiency.

We are tired from all the fear and we are tired of filling out forms. We are tired of having kept the supply and chow and ambulance lines going to the front for over 21 months now. Like a returning army our people have come home, and many are gravely scarred. For some the wounds are obvious, and the thank you for your services and sorry for your losses are heartfelt. For far too many the wounds are unseeable and barely reachable and require patience, not stitches.

The tidal wave of wounded families that I am seeing is unparalleled in my 15 years of practice. I am seeing the harms within: between parents, parents and children, children, children and schools; between parents and peers; between my patients' blood pressures and their suffocating, sedentary fears; between health-giving practices and the despairs of a war zone.

We have all been hearing about this war we are in and I am tired of hearing about how much preventative care has been deferred and ignored, and how much the mental health and well-being of the nation needs attention. The country is devastated, and to continue to keep it on a war-footing is prolonging the devastation. It is time for COVID to put down its weapons. The eagle has landed. It is time to start building schools.

See the original post:
Opinion/McGonigle: It is time to stop fighting - The Providence Journal

FRANKLIN, Tenn. - Today, Mitsubishi Motors North America (MMNA) unveiled the 2022 Outlander SUV that will carry Team 207 throughout the Rebelle Rally on October 7-16.

* 2022 Outlander livery celebrates 2001 Dakar rally victory of Jutta Kleinschmidt, first woman to ever win the famed event

* U.S. military veterans and a PTSD service-dog named Sammy talk about the invisible scars of war, overseas deployments, returning home, and family

The lightly modified vehicle sports a special livery that pays tribute to the brand's history-making Dakar Rally win twenty years ago, when Jutta Kleinschmidt drove a Mitsubishi Pajero to victory, becoming the only woman ever to win the world-famous Dakar. Before the event even starts, the crew of Team 207 are already winners.

Sisters-in-law Selena 'Mason' Converse and Erin Mason are not afraid of a challenge. As an emergency medical services technician in the U.S. Air Force, Mason provided emergency medical care in both non-combat and combat situations. As an aviation structural mechanic, you could find Erin weaving in and out of incoming plane traffic on U.S. Navy aircraft carriers. They joined the military, right out of high school, to establish their independence, seek adventure, and serve their country.

This October, Mason and Erin, along with Mason's two-and-a-half-year-old, PTSD-trained service dog, Sammy, are embarking on a new adventure, further testing themselves and their 2022 Mitsubishi Outlander. They will represent MMNA and veterans nonprofit Record the Journey (RTJ) on the nine-day, 2000-km, all-women, off-road Rebelle Rally.

Described by veterans who competed with Mitsubishi Motors and RTJ in past years as a 'mini-deployment,' Mason, Erin and Sammy will face a grueling schedule of long days and short nights, challenging and diverse off-road terrain, and the memories of their service - the good and the bad - head on.

We sat down with the team, before they head out on the Rebelle, to learn more of their stories.

FIVE QUESTIONS WITH U.S. AIR FORCE VETERAN SELENA 'MASON' CONVERSE

Team Record the Journey Driver, Owner of Mason Converse Media

1. On paper, you are a wife, mother, combat veteran and small-business owner. How do you define yourself? I am all of those things with all of my heart. Those titles are a huge part of me and have helped form who I have become. I have not seen any of those titles as a job, rather, an opportunity that I have been gifted. I've grown to know that I am a caretaker. I consider myself as caring and creative and I am the happiest when I am caring for others and/or utilizing my creative talents.

2. You were an emergency medical services technician in the U.S. Air Force - stationed all over the U.S. and once deployed to Afghanistan. Help us understand, as much as a civilian could, what that was like. My job as an EMT for the U.S. Air Force was incredible, and for the most part, very rewarding. I saved lives, cared for countless families and was able to train future medics for the U.S. Air Force and Navy. I was initially trained at the EMT - basic level, and I was able to work in the emergency room, on an ambulance and in multiple specialties around the hospital.

Realizing my love for teaching, I became a certified Nationally Registered EMT (NREMT) Instructor. Eventually, I deployed to Afghanistan and worked in the intensive care unit and the emergency room. I cared for injured U.S. soldiers, our allies, as well as confirmed enemy combatants.

My job at home, when not deployed, was primarily focused on preventative medicine - keeping soldiers (and their families) healthy. My job while I was deployed was rather different. There was no preventative medicine, only reactive medicine to the most traumatic injuries with limited supplies. After returning from Afghanistan, I was hand-selected to become a military training instructor at the Military Education and Training Center in Texas.

3. You left the military after almost 13 years to put down roots and raise your family, and you started your company, Mason Converse Media. Everything was going well. When did you begin realizing you might have PTSD? PTSD came in waves. I didn't just leave the military and feel this intense overwhelming PTSD sensation - it is not quite like that. I experienced traumatic things during my deployment, and they forever changed who I am. But while in the military, we were trained to deal with stress and trauma extremely well.

After leaving the military, I had the mindset that I 'had PTSD,' but I did not 'suffer from PTSD'. I assumed the things I felt were just transition stress and that they would go away on their own. What I did start to notice was that I perceived and dealt with certain things differently than my non-military friends. Things that I worried about, or that caused me anxiety, did not cause others to have the same emotional triggers.

I lost my parents as a child. Since then, I've used the avoidance tactic to manage extreme stress: if I didn't face it, discuss it, or even think about it, then it couldn't affect me. I applied this same tactic to my post-military life, and it 'worked' for quite some time. The pandemic was a huge PTSD trigger for me and a turning point for me to openly evaluate and discuss my PTSD symptoms.

4. You are the proud mother of three human children, and Sammy, a two-and-a-half-year-old, all-black German Shepherd. Tell us how Sammy entered your life. Sammy entered my life as an unexpected blessing. She was born at a time that I was navigating my PTSD symptoms and not openly discussing any of them. At that same time, my husband's canine best friend of 13 (Joe) years was getting to the end-stage of life. A neighbor of ours offered my husband a German Shepherd puppy, Sammy, to help with the transition and eventual loss of his dog. Sammy came to us much sooner than expected, at just four weeks old (another story for another day), and I spent the next four weeks being mom to the tiniest bear-cub looking puppy.

Joe passed shortly thereafter, and Chuck did not yet feel connected with Sammy. We thought it would just take time for the bond to form, so we kept her and spent the next year training her. Sammy was smart and was ready for a meaningful role. At that time, I had begun therapy for PTSD. The idea of having Sammy trained as a service dog came up, and it really became obvious that she was truly meant for me and not my husband.

5. Together, you, Sammy and your sister-in-law Erin make up Team 207, Mitsubishi Motors' entry into the 2021 Rebelle Rally. As you head into the dunes, why is it important for you to tell your story? The biggest key to managing my PTSD was being able to admit the issues and symptoms I was experiencing. When you separate out the individual symptoms or triggers, then you can treat the PTSD more effectively. Many people assume the treatment for PTSD is taking a prescription medicine. It can be, but that's not the treatment for everyone.

Part of my PTSD treatment is the use of a service dog. Service dogs provide treatment of PTSD symptoms, much like a medication could, but other times better than medication can. Service dogs are specifically trained to perform tasks to aid in a person's disability.

As a team of female veterans, I believe it is so important to share our story and help others understand that PTSD does not have to control your whole life - it is possible to live the life you want while managing PTSD. Sammy's participation in the Rebelle Rally will go a long way to doing that.

FIVE QUESTIONS WITH U.S. NAVY VETERAN ERIN MASON

Team Record the Journey Navigator, Owner & Farmer, Mason Wholesale Greenhouses

1. Congratulations (and awe) are in order! You just welcomed a new baby girl, Selena, to your family, and she will be just six weeks old when you head out for the Rebelle. What is motivating you to take this on so soon? By competing in an all-woman rally, I believe I am sending my two young girls a message that anything is possible and that some things are meant to be. A year ago, Rachael Ridenour, founder of veterans non-profit Record the Journey, picked us to go on this adventure to represent her charity and Mitsubishi. Before Mason and I knew it, we were driving across the country to learn technical driving and navigation skills from Rachael, and in between trips to the desert, were on Zoom calls, trying to absorb as much as we could. Around Christmas, I learned I was expecting, and was relieved to learn the due date - I'd be cutting it close, but I could still compete in the Rally. It was a good pregnancy, and even better delivery, so it really feels meant to be. I know my daughter Selena will be cheering me on from home. As if the rally wasn't challenging enough, I will also be pumping so I can return to breast feeding when I get home.

2. You joined the military, in your words, as soon as you could. You were young, wide-eyed and from a small town. What were those first years like for you? Sitting across from the recruiter, signing my papers to join the military, I knew I was leaving my small town for something bigger, and I was right. If you've never seen an aircraft carrier, it's beautiful, the way the planes come in and out. It's like controlled chaos, like synchronized swimming - it's an adrenaline rush. My first years were defined by adventure. My first assignment was Virginia Beach, and I was crossing the seas in an aircraft carrier in no time. I would volunteer for every detachment and work to achieve every qualification, chasing fighter jets across the world, knowing it would mean more adventure, and that's exactly what I wanted.

3. What deployment stands out to you as having the biggest personal impact. My deployment on the USS George H. W. Bush was by far the most impactful time I spent serving my country. It was the ship's maiden deployment - we sailed for eight months, from Virginia, to the Rock of Gibraltar, to the Suez Canal, around the Horn of Africa and into the Arabian Gulf. Along the way, we made stops in England, Italy, France, Spain, Bahrain and Dubai. It was equally thrilling and grueling. I learned what my body was capable of, by operating on minimal sleep and maximum exhaustion. When we arrived back in the States, I quickly came to grips with the mental toll as well, as a good friend from the deployment took his own life. Losing him is one reason I am so passionate about mental health awareness and PTSD advocacy for my military brothers and sisters.

4. You would have stayed in the service longer, if that was an option. Describe your transition out of the military and into civilian life. The year I left, the government was downsizing the military, and was not renewing thousands of service member contracts. I thought I was going to spend my whole life in the Navy, but life had other plans. Navigating the transition was lonely and confusing - all of a sudden, I felt like I didn't have a purpose. In the service, we are a family. We grow together. We experience life and death, births and divorces together. I was a shoulder to cry on when a friend was on a deployment, watching a YouTube video of their baby taking their first steps. I went from traveling the world, to being stuck in one place. Re-entering the civilian world, returning to people who never left... they can't understand what we are going through. It took me a couple years to adjust back to civilian life and to find my identity outside of the military. I became a civilian mechanic... I met my husband, also a veteran, who served in the Air Force. I eventually finished school and started a family. There will always a part of me that can only be filled up by my military family, so I try to be around them as much as I can.

5. Now, you run Mason Wholesale Greenhouses with your husband - also former military. Tell us about the business and how you got started. We started when my husband was transitioning out of the military. He worked at a nursey in high school and has a real way with plants. I found a place called Archi's Acres in Southern California that has a six-week course, designed to introduce veterans to sustainable agriculture, and I signed us both up. While we were there, my husband received a call that his former boss, the nursery owner, passed away, and his wife wanted to sell the property to us! Now in East Texas, we grow organic produce and crops in greenhouses. We aim to keep a small carbon footprint and really enjoy sharing our passion for sustainable agriculture with our community. The soil therapy has been so good for me! In the future, we hope to invite other veterans to our property for off-grid retreats, to help others find the same peace.

FIVE QUESTIONS SAMMY THE SERVICE DOG

PTSD-Trained, 2.5-Year-Old, All-Black German Shepherd

1. Describe your perfect day. I love to go on adventures with my family - my mom, dad, my human sisters and my brother. My mom owns a 4x4 off-road adventure photo and video company, so it is kind of part of the territory. We go to lakes, where I am learning to fetch rocks and sticks off of the lake bottom, and we go to the desert, where I am learning to help mom dig big trucks out of the sand. (Should come in handy for Rebelle, right?) By nature, I am curious, confident and loyal, making me the pawfect adventure partner. Oh, and I absolutely love frisbee. I could play frisbee for hours. At the end of a long day of adventures, or a long day on PTSD-service duty, I love my quiet time. Did I mention I love frisbee?

2. What does it mean to be a PTSD-trained service animal? My mom is my hero. She served in the U.S. Air Force for 13 years. (Planes are like frisbees, but much bigger.) As an emergency medical services technician, she skillfully and bravely attended to men and women on both sides of armed conflict. But when she came home, it was hard for her to really feel at home. She had flashbacks and nightmares; sometimes she felt sad, isolated, angry and scared. Not to brag, but I am pretty intelligent and observant, and I take direction really well, so I am kind of the perfect service animal. I went through intense training, learning about all of the things that could trigger my mom's anxiety, and how to make her, and my whole family, feel safe. Now, everywhere they go - on adventures, to the grocery store, to bed at night - I have their back.

3. And we understand your vest isn't just a fashion accessory... It is a very cool vest, yes, but it is much more. It is like a super-hero cape. When I put on my vest, it makes me feel powerful, and it reminds me of my training. It means that I am on duty, and no one can mess with me or my family. When I take off my vest, I am just your average 2.5-year-old puppy. I like to play frisbee... run, jump, roll, scratch and snuggle with my siblings. I take my job seriously; I take my play time seriously, and I take my down time seriously. You have to, in this business. Sometimes, it is important for me to find a quiet space, sit, and reflect on the day.

4. All-black German Shepherds are extremely rare. How do you keep that beautiful coat so clean? Why, thank you. It's true, my line of work can be ruff on hair, skin, nails and teeth. To keep me looking and feeling good on the Rebelle, pet wellness company Skout's Honor has loaded down our 2022 Mitsubishi Outlander with array of probiotic grooming and wellness essentials, including Probiotic Shampoo + Conditioner, Prebiotic Pet Balm, Probiotic Deodorizer and Paw Spray. Also, Mitsubishi has outfitted us with some pretty cool, Team 207 swag, including a custom bandana from http://www.mymitsubishistore.com. Shout out to my sponsors!

5. What are you most looking forward to about Rebelle Rally? Well, I have done my research, and there are a lot of car commercials with dogs in them, but none can do what I can. I don't see any other pups protecting their mom from danger, or digging their team out of sand dunes. I will be the first animal to ever compete in the Rally, just saying... In all seriousness, I really identify with the spirit of Rebelle - the adventure, the strategy, the girl power! My mom can do anything, with me at her side. I hope her story inspires others to be authentic, brave and embrace adventure - just like us.

For more information on the 2022 Mitsubishi Outlander, visit https://www.mitsubishicars.com/outlander/2022.

About Mitsubishi Motors North America, Inc.

Through a network of approximately 330 dealer partners across the United States, Mitsubishi Motors North America, Inc., (MMNA) is responsible for the sales, marketing and customer service of Mitsubishi Motors vehicles in the U.S. MMNA was the top-ranked Japanese brand in the J.D. Power 2021 Initial Quality study, ranking third overall and tied with Lexus. In its Environmental Targets 2030, MMNA's parent company Mitsubishi Motors Corporation has set a goal of a 40 percent reduction in the CO2 emissions of its new cars by 2030 through leveraging EVs - with PHEVs as the centerpiece - to help create a sustainable society.

With headquarters in Franklin, Tennessee, and corporate operations in California, Georgia, Michigan, New Jersey, Texas, Florida and Virginia, MMNA directly and indirectly employs more than 8,000 people across the United States.

For more information on Mitsubishi vehicles, please contact the Mitsubishi Motors News Bureau at 615-257-2698 or visit media.mitsubishicars.com.

Contacts

Jeremy Barnes

Senior Director, Communications and Events

jeremy.barnes@na.mitsubishi-motors.com

Mobile: 714-296-1402

Lauren Ryan

Manager, Communications and Events

lauren.ryan@na.mitsubishi-motors.com

Mobile: 404-862-8286

Read this article:
Mitsubishi Motors : Unveils 2022 Outlander for 2021 Rebelle Rally; Introduces the Military Veterans Who Will Contest the Event - marketscreener.com

Human genetic enhancement or human genetic engineering refers to human enhancement by means of a genetic modification. This could be done in order to cure diseases (gene therapy), prevent the possibility of getting a particular disease[1] (similarly to vaccines), to improve athlete performance in sporting events (gene doping), or to change physical appearance, metabolism, and even improve physical capabilities and mental faculties such as memory and intelligence.These genetic enhancements may or may not be done in such a way that the change is heritable (which has raised concerns within the scientific community).[2]

Genetic modification in order to cure genetic diseases is referred to as gene therapy. Many such gene therapies are available, made it through all phases of clinical research and are approved by the FDA. Between 1989 and December 2018, over 2,900 clinical trials were conducted, with more than half of them in phase I.[3] As of 2017, Spark Therapeutics' Luxturna (RPE65 mutation-induced blindness) and Novartis' Kymriah (Chimeric antigen receptor T cell therapy) are the FDA's first approved gene therapies to enter the market. Since that time, drugs such as Novartis' Zolgensma and Alnylam's Patisiran have also received FDA approval, in addition to other companies' gene therapy drugs. Most of these approaches utilize adeno-associated viruses (AAVs) and lentiviruses for performing gene insertions, in vivo and ex vivo, respectively. ASO / siRNA approaches such as those conducted by Alnylam and Ionis Pharmaceuticals require non-viral delivery systems, and utilize alternative mechanisms for trafficking to liver cells by way of GalNAc transporters.

Some people are immunocompromised and their bodies are hence much less capable of fending off and defeating diseases (i.e. influenza, ...). In some cases this is due to genetic flaws[clarification needed] or even genetic diseases such as SCID. Some gene therapies have already been developed or are being developed to correct these genetic flaws/diseases, hereby making these people less susceptible to catching additional diseases (i.e. influenza, ...).[4]

In November 2018, Lulu and Nana were created.[5] By using clustered regularly interspaced short palindromic repeat (CRISPR)-Cas9, a gene editing technique, they disabled a gene called CCR5 in the embryos, aiming to close the protein doorway that allows HIV to enter a cell and make the subjects immune to the HIV virus.

Athletes might adopt gene therapy technologies to improve their performance.[6] Gene doping is not known to occur, but multiple gene therapies may have such effects. Kayser et al. argue that gene doping could level the playing field if all athletes receive equal access. Critics claim that any therapeutic intervention for non-therapeutic/enhancement purposes compromises the ethical foundations of medicine and sports.[7]

Other hypothetical gene therapies could include changes to physical appearance, metabolism, mental faculties such as memory and intelligence.

Some congenital disorders (such as those affecting the muscoskeletal system) may affect physical appearance, and in some cases may also cause physical discomfort. Modifying the genes causing these congenital diseases (on those diagnosed to have mutations of the gene known to cause these diseases) may prevent this.

Also changes in the mystatin gene[8] may alter appearance.

Behavior may also be modified by genetic intervention.[9] Some people may be aggressive, selfish, ... and may not be able to function well in society.[clarification needed] There is currently research ongoing on genes that are or may be (in part) responsible for selfishness (i.e. ruthlessness gene, aggression (i.e. warrior gene), altruism (i.e. OXTR, CD38, COMT, DRD4, DRD5, IGF2, GABRB2[10])

There is some research going on on the hypothetical treatment of psychiatric disorders by means of gene therapy. It is assumed that, with gene-transfer techniques, it is possible (in experimental settings using animal models) to alter CNS gene expression and thereby the intrinsic generation of molecules involved in neural plasticity and neural regeneration, and thereby modifying ultimately behaviour.[11]

In recent years, it was possible to modify ethanol intake in animal models. Specifically, this was done by targeting the expression of the aldehyde dehydrogenase gene (ALDH2), lead to a significantly altered alcohol-drinking behaviour.[12] Reduction of p11, a serotonin receptor binding protein, in the nucleus accumbens led to depression-like behaviour in rodents, while restoration of the p11 gene expression in this anatomical area reversed this behaviour.[13]

Recently, it was also shown that the gene transfer of CBP (CREB (c-AMP response element binding protein) binding protein) improves cognitive deficits in an animal model of Alzheimers dementia via increasing the expression of BDNF (brain-derived neurotrophic factor).[14] The same authors were also able to show in this study that accumulation of amyloid- (A) interfered with CREB activity which is physiologically involved in memory formation.

In another study, it was shown that A deposition and plaque formation can be reduced by sustained expression of the neprilysin (an endopeptidase) gene which also led to improvements on the behavioural (i.e. cognitive) level.[15]

Similarly, the intracerebral gene transfer of ECE (endothelin-converting enzyme) via a virus vector stereotactically injected in the right anterior cortex and hippocampus, has also shown to reduce A deposits in a transgenic mouse model of Alzeimers dementia.[16]

There is also research going on on genoeconomics, a protoscience that is based on the idea that a person's financial behavior could be traced to their DNA and that genes are related to economic behavior. As of 2015, the results have been inconclusive. Some minor correlations have been identified.[17][18]

George Church has compiled a list of potential genetic modifications based on scientific studies for possibly advantageous traits such as less need for sleep, cognition-related changes that protect against Alzheimer's disease, disease resistances, higher lean muscle mass and enhanced learning abilities along with some of the associated studies and potential negative effects.[19][20]

Link:
Human genetic enhancement - Wikipedia

Published: Oct. 5, 2021 at 8:00 AM EDT|Updated: 10 hours ago

EMERYVILLE, Calif. and BOULDER, Colo., Oct. 5, 2021 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced that Amyris has licensedthe Onyx genome engineering platform from Inscripta, a leading gene editing technology company. Amyris and Inscripta will also explore joint research and development opportunities to expand the Onyx platform functionality.

Amyris' product development and formulation teamuses a proprietaryLab-to-Market operating system to develop and scale a growing portfolio of sustainable ingredients. The Onyx platform automates benchtop biofoundry activity and will bring greater genetic diversity and value to Amyris' ingredient development pipeline, complementing Amyris' existing Lab-to-Market operating systemwith the goal of improving efficiency and reducing timelines for the development of future molecules. To date, Amyris has successfully commercialized 13 sustainable ingredients, which are formulated in over 20,000 products and used by over 300 million consumers, demonstrating the growing demand for sustainable products with clean and effective ingredients.

Automated, high-throughput gene editing is revolutionizing the writing of genomes the way next-generation sequencing transformed the reading of genomes. Inscripta is the first company to deliver an integrated and intuitive benchtop platform that will expand access to scalable, robust genome engineering and help scientists develop solutions to some of today's most pressing challenges.

"Amyris has shown the world how new products can be made more sustainable through biology. Their team has high proficiency in utilizing cutting-edge technology, and we are excited they will be pioneering the use of our platform," said Sri Kosaraju, President and CEO of Inscripta. "We have great regard for Amyris' mission, and we are committed to seeing the Onyx platform become a substantial contributor to new clean chemistry products in the future."

"The Onyx platform offers significant potential for generating greater genetic diversity in our projects, which we expect to lead to more efficient product innovation," said Sunil Chandran, Senior Vice President of Research and Development at Amyris. "Inscripta's platform seamlessly integrates with our own and opens up new experimentation avenues for our scientists to continue bringing unique bio-based products to customers. We pride ourselves on continuous innovation and expect Onyx to help us expand our pipeline, while achieving lower costs and reducing time to market."

For more information about Amyris visit amyris.comand to learn about Onyx, visitwww.inscripta.com/products.

About InscriptaInscripta is a life science technology company enabling scientists to solve some of today's most pressing challenges with the first benchtop system for genome editing. The company's automatedOnyx platform,consisting of an instrument, consumables, assays, and software, makes CRISPR-based genome engineering accessible to any research lab. Inscripta supports its customers around the world from facilities in Boulder, Colorado; San Diego and Pleasanton, California; and Copenhagen, Denmark. To learn more, visitInscripta.comand follow@InscriptaInc.

About AmyrisAmyris (Nasdaq: AMRS) is a science and technology leader in the research, development and production of sustainable ingredients for the Clean Health & Beauty and Flavors & Fragrances markets. Amyris uses an impressive array of exclusive technologies, including state-of-the-art machine learning, robotics and artificial intelligence. Our ingredients are included in over 20,000 products from the world's top brands, reaching more than 300 million consumers. Amyris is proud to own and operate a family of consumer brands - all built around its No Compromise promise of clean ingredients: Biossanceclean beauty skincare, Pipetteclean baby skincare, Purecane, a zero-calorie sweetener naturally derived from sugarcane, Terasanaclean skincare treatment, Costa Brazil luxury skincare, OLIKA hygiene and wellness, Rose Inc. clean color cosmetics and JVN clean haircare. For more information, please visit http://www.amyris.com.

Amyris, the Amyris logo, No Compromise, Biossance, Pipette, Purecane, Terasana, Rose Inc. and Lab-to-Market are trademarks or registered trademarks of Amyris, Inc. in the U.S. and/or other countries.

Forward-Looking StatementsThis release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements.These forward-looking statements include, among other things, statements regarding Amyris' expectation of exploring additional research and development opportunities with Inscripta in the future and its expectation that Onyx will help Amyris expand its pipeline while achieving lower costs and reducing time to market. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to any delays or failures in the successful launch of a clean skincare brand; potential delays or failures in development, production, regulatory approval and commercialization of products, risks related to Amyris' reliance on third parties; Amyris' liquidity and ability to fund operating and capital expenses; and other risks detailed from time to time in filings Amyris makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Amyris disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise.

View original content to download multimedia:

SOURCE Amyris, Inc.

The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.

Visit link:
Amyris Partners with Inscripta to Enhance Development of Sustainable Ingredients Using the Onyx Genome Engineering Platform - WWNY

Although acreage under GMO crop cultivation has expanded rapidly worldwide since GMOs first began to be grown in the mid to late 1990s, production remains highly concentrated in a handful of crops such as cotton, soybeans and corn which are grown in a few countries. Of the 190.4 million hectares (469.5 million acres) of GMO crops planted in 2019 for example, the US, Brazil, Argentina and Canada accounted for 84.5% of the total.

[su_panel color=#3A3A3A border=1px solid #3A3A3A radius=2 text_align=left]This is the first part of a two-part series.[/su_panel]

Most of the developing world has spurned the planting of GMO crops for a variety of reasons. First is their historical colonial links to countries in Europe, where GMOs are shunned because of a perception they are not natural. A reliance on the precautionary principle to prevent any possible risks to the health of humans and animals and the environment and active opposition by the influential organic food and anti-GMO lobby have also inhibited the development of GMO crops in Europe.

This reluctance of European nations to embrace GMOs has influenced developing countries, particularly as the EU is a major export market for many of them. The EUs strict regulatory approval system and stringent labeling requirements clearly are an inhibiting factor restraining the development of GM crops in many developing nations.

In 2020, the European Academies Science Advisory Council noted:

The EU over-regulation of GMOs had negative impact on science and innovation in developing countries who feared for their export markets and who were inclined to look to the EU to express leadership in research and development.

Unlike the US, the EU does not encourage or promote the development of GMOs in its foreign assistance programs to developing countries. A FDA website entitled, How GMO Crops Impact our World for example specifically states, The U.S. Agency for International Development (USAID) is working with partner countries to use genetic engineering to improve staple crops, the basic foods that make up a large portion of peoples diets. The USDA also publishes annual agricultural biotechnology reports for many developing countries that track their receptiveness to developing GE crops.

Second, the antipathy of many major western NGOs such as Greenpeace and Friends of the Earth to GMOs has influenced many developing countries. Many of these NGOs have operations or affiliates or contribute money to NGOs in the developing world. As a result, many environmental and food NGOs in developing nations also vehemently oppose the development of GMO crops. They are following the lead of their counterparts in western nations. According to Greenpeace, one of the most influential environmental NGOs:

Genetically modified crops encourage corporate control of the food chain and pesticide-heavy industrial farming. GM plants can also contaminate other crops and lead to super weeds. This technology must be strictly controlled to protect our environment, farmers and independent science.

Finally, a paper published in Food and Chemical Toxicology by the French molecular biologist Gilles-ric Sraliniin 2012 that purported to link consumption of GMOs to cancer influenced many developing countries to restrict their development as it seemed to highlight the worst fears of the opponents of GMOs. Kenya for instance, imposed a strict import ban in 2012 on GMOs citing the Seralini study. Although the study was subsequently debunked and retracted, the damage was done. The discredited paper was nonetheless promoted by GMO opponents and the perception that GMOs were dangerous lingered on for many years.

In recent years however, it has become increasingly apparent to many developing nations that genetic engineering of crops can be an important tool in helping feed a growing population at a time of climate change and when urbanization and desertification are reducing the amount of land for farming. Without a more productive farming sector, many developing nations will face a rising food import bill because of a swelling population. This is in sharp contrast to the developed world, where the population is growing at a very marginal rate or is actually shrinking:

As a result, it is imperative that many developing nations find a means of increasing their agricultural production, boost farm income and curb the cost of food imports. Genetic engineering offers that means.

This was Part One of a two-part post on the growing acceptance of GM foods and crops in the developing world. Part Two will review what specific actions countries are taking with certain foods.

Steven E. Cerier is a freelance international economist and a frequent contributor to the Genetic Literacy Project.

See the original post here:
Viewpoint: Part 1 Opposition stirred by anti-GMO advocacy group propaganda fading in the developing world, as more countries embrace crop...

While plenty of established companies have expertise in cultures for use in products such as yogurt and beer, Kingdom Supercultures is deploying computational biology to interrogate a vast database of microorganisms (yeast, bacteria, fungi etc) to identify combinations of microbes that will deliver specific functional or nutritional benefits, chief science officer Ravi Sheth told FoodNavigator-USA.

While the microbes may help improve the nutritional profile of certain products for example by enabling the production of kombuchas with less sugar - Kingdom Supercultures is not really a probiotics company, he stressed.

Nor is it a synthetic biology or precision fermentation company thats genetically engineering microbes to produce target proteins or other compounds and then engaging in complex downstream extraction and purification processes, explained Sheth. The combinations of cultures themselves which are all Non-GMO are the ingredients it plans to sell.

Were taking cultures already found in nature and combining them into specific novel combinations, and so we don't actually have to use any genetic engineering.

He added: Only in the last few years or so has it been possible to sequence these foodborne microorganisms, identify them, and predict their metabolic functionality, and so we've been able to leverage technologies from only the last couple of years, and build a biobank containing tens of thousands of microorganisms that are much broader in diversity than the kind of culture collections these legacy companies have.

The second thing we bring is the computation and data science capability, so were mining this data and using a number of novel algorithms and approaches we have internally to narrow down this design space and get to very specific cultures, in very specific ratios, that lead to these emergent functionalities, he explained.

We look at these almost like Lego building blocks, which we can rearrange into different combinations, and then create a community of them that delivers an emergent functionality that the individual strains don't have. Its like one plus one equals three.

Kingdom Supercultures has two main types of products, added Sheth, who said the firm is inactive R&D work with some of the largest most innovative CPG companies... and some of these projects are pretty late stage.

The first product type is starter cultures that can be used for things like plant based yogurts, cheeses, beers and wines. The second type is bioactives or other functional ingredients that can act as preservatives or elicit some sort of functional impact on the microbiome, exert nutritional benefits.

If you want to describe what the company does in a nutshell, he added:It took our ancestors hundreds of thousands of years to discover that hey, if I leave milk out it turns into yogurt or if I leave sugar tea out it turns into kombucha, what we can do is rationally design that process.

* This follows a $3.5M seed round with participation from Sequoia, Y-Combinator, Lakehouse Ventures, and Brand Foundry Ventures in 2020.

Follow this link:
Kingdom Supercultures raises $25m to expand Non GMO suite of microbes to unlock new flavors, textures, and functionalities in food & beverage -...

NYC demonstrators rally against COVID-19 vaccine requirements

NY Gov. Kathy Hochul has said she will take steps to replace medical personnel who refuse to meet the vaccination requirement.

USA TODAY, Associated Press

As COVID-19 vaccine mandates take effect across the U.S., one article circulating on social media claims getting jabbed in the arm may no longer be necessary.

"Vaccine Hesitant?" reads the headline of the Sept. 21 article published by an online outlet called Vision Times. "US Researchers Are Engineering Lettuce and Spinach to Carry mRNA COVID Jabs."

A University of California, Riverside research group, in collaboration with the University of California San Diego and Carnegie Mellon University, is reported as spearheading the scientific effort. The article details the study's research plans but makes no additional mention of the headline's reference to COVID-19 vaccines aside from describing how the mRNA vaccines work.

Fact check: Inhaling hydrogen peroxide for COVID-19 is dangerous, experts warn

The potential for splicing COVID-19 vaccines into food was echoed by former National Security Adviser Michael Flynn during a recent appearance on a podcast called "Thrivetime Show: Business School Without the B.S." In a viral clip shared to Twitter on Sept. 22, Flynn says he read an article where "they're talking about putting the (COVID-19) vaccine into salad dressings or salad."

As far-fetched as vaccine-infusedspinach and lettuce sounds, the claim is not entirely unfounded.

Researchers at UC Riverside and its collaborating universities are working on potentially turning plants into edible vaccine factories. But they'renot doing itfor COVID-19 specifically, and such foods won't be available in your local supermarket anytime soon.

USA TODAY reached out to Vision Times and Flynn for comment.

The National Science Foundation gave a UC Riversideresearch group $500,000 to study genetically engineering plants with mRNA, a molecule contained in the Pfizer-BioNTech and Moderna COVID-19 vaccines that isnormally used by our cells to make protein.

The effort was announced in a Sept. 16 press release.

Fact check: COVID-19 vaccination has no effect on blood color

But the study is looking generally toward all mRNA vaccines not COVID-19 specifically andwon't be available for human useanytime soon, said lead researcher Juan Pablo Giraldo, associate professor in the department of botany and plant sciences.

"This research will take a couple of years to show proof of concept of the technology," he wrote in an email to USA TODAY. "If successful, it will need more studies and several more years for people to use leafy greens as mRNA vaccine factories."

The idea behind using plantshas to do with mRNA vaccines' temperature requirements. Because the molecule needs to be transported and stored under cold conditions to maintainstability, researchers hope their study will help overcome this challenge and enable storage at room temperatures, according to the press release.

Fact check: False claim that cancer has spiked as a result of COVID-19 vaccines

In order to achieve this, genetic material contained in mRNA vaccines will be inserted into small, disk-like structures within plant cells called chloroplasts, solar panel-like structures that convert sunlight into chemical energy.

"Ideally, a single plant would produce enough mRNA to vaccinate a single person," Giraldo said in the release. "We are testing this approach with spinach and lettuce and have long-term goals of people growing it in their own gardens. Farmers could also eventually grow entire fields of it."

Based on our research, we rate PARTLY FALSE the claim spinach and lettuce are being genetically engineered with COVID-19 mRNA vaccines. Researchers at UC Riverside are indeed studying whether edible plants like spinach and lettuce can be genetically engineered to produce genetic material contained in mRNA vaccines. But thestudy isn't geared specifically toward COVID-19 vaccines. And the effort is in its infancy,meaning a product in this vein is years away from becoming reality.

Thank you for supporting our journalism. You can subscribe to our print edition, ad-free app or electronic newspaper replica here.

Our fact-check work is supported in part by a grant from Facebook.

Read more from the original source:
Fact check: Genetically engineering your salad with the COVID-19 vaccines? We're not there yet. - USA TODAY

Genetically engineered (GE) crops, which have been commercially available for 25 years, have been widely misunderstood and under-appreciated, especially by certain news outlets. Arguably, the worst offender among the mainstream media has been the New York Times, whose manifold shortcomings in reportage and commentaries over many years are describedhereandhere.

Perhaps some glimmer of enlightenment toward genetic engineering is belatedly emerging. We were somewhat encouraged recently by Learning to Love GMOs, from science writer Jennifer Kahn in the New York Times Magazine in July. (GMO, or genetically modified organism, is a rather fluid, meaningless term used to refer to an organism modified with highly precise and predictable molecular techniques.)

At the risk of nitpicking, however, we felt that she over-emphasized the handful of genetically engineered farm products intended to be sold directly to consumers, while omitting the more important but less sexy story: the huge, palpable, proven benefits that GE crops have provided since they first hit the marketplace. Not surprisingly, there was also no mention of her newspapers decades-long, ugly history of disparaging and misrepresenting genetic engineering.

The big picture here is important, especially to Americas preeminence in the science, technologies, and application of genetic engineering. The U.S. is an agricultural powerhouse, but it is plagued by the eternal menaces to farming, including drought, floods, weeds, and pestilenceall of which are approachable by GE, in which America leads the world. Moreover, as valuable as GE is to the economic development of advanced countries, it is literally a life-saver to less developed ones. Kahn broaches none of this.

Kahn begins with a lively description of plant biologist and British professor Cathie Martin and her fabulous,GE cancer-fighting tomatoes. These fruits, dark purple in color, produce high amounts ofanthocyanins, compounds usually associated with blueberries and containing antioxidant activity. Professor Martin was able to demonstrate that cancer-prone mice fed these tomatoes lived 30% longer and were also less susceptible to inflammatory bowel disease than mice fed ordinary, non-engineered tomatoes.

The article discusses other GE specialty fruits, such as virus-resistantRainbow Papayas(which rescued Hawaiis papaya industry from oblivion) and non-browningArctic Apples, which have found valuable niches in todays market. Kahn also makes honorable mention of other GE fruits and vegetables in development, such as tastier berries and sweeter, kid-friendly kale, among many others.

Readers are left with the impression that such new crop varieties that will tickle consumers taste buds and satisfy their nutritional needs are the goaland the real valueof GE, and that these developments are just around the corner thanks to plant genetic engineering. Could that, Khan speculates, spell the turning point for widespread public acceptance of genetically engineered crops?

The problem is that Khan misidentifies the consumers who most need and would benefit from GE advances. Since their introduction in the mid-1990s, she writes, GMOs have remained wildly unpopular with consumers, who see them as dubious tools of Big Ag, with potentially sinister impacts on both people and the environment. Kahn frames the problem of GE production as the plight of small, artisanal food growers due to federal regulation that favors global agricultural conglomerates. [J]ust to go through the FDA approval process would cost a million dollars. Adding USDA approval could push that amount even higher, she writes. The regulatory barriers are, in fact, astronomical: it costs about$136 millionto bring a GE crop plant to market. This is the primary reason more than 99% of such crop plants are those that are grown at huge scale. (What makes this absurd is that plants modified with less precise, less predictable, conventional,pre-moleculartechniques arevirtually unregulated.)

The solutionadvances in the development of small-scale, bespoke GMO produceis inviting to Kahn, whose efforts seem directed at convincing WWWs:

[Professor] Martin is perhaps onto something when she describes those most opposed to GMOs as the WWWs: the well, wealthy, and worried, the same cohort of upper-middle-class shoppers who have turned organic food into a multibillion-dollar industry. If youre a WWW, the calculation is, GMOs seem bad, so Im just going to avoid them, she said. I mean, if you think there might be a risk, and theres no benefit to you, why even consider it?

Although its true that the potential for new, delicious, nutritious GE fruits and vegetables is vast, Kahn ignores the enormous success of genetically engineered crops across much of the world over the past three decadesimportantly, for more than just the well, wealthy, and worried. GE crops have in fact made food more affordable and proved to be a vital life-saving source of food and agricultural inputs for much of the developing world. Its time to set the record straight.

WORLDWIDE IMPACTS OF GE INNOVATION

Kahn laments that much of the effort in plant genetic engineering has been to produce improved varieties of our most commercially important crops, such as pest-resistant corn and cotton, herbicide-tolerant soybeans and canola (in order that weeds can be controlled more safely and effectively than by foliar spraying), and other agronomic traits such as resilience to flooding or drought. Although consumers may be unaware of these achievements, they have been eagerly embraced by farmers and critical to progress in agriculture. The acreage farmed with genetically engineered crops, which reached almost ahalf-million acres worldwide in 2018, increases every year, particularly in developing countries. (And that figure is only the official acreage; there is a great deal more cultivation with seeds obtained on theblack marketby farmers in countries where theyre not yet approved.)

In fact, the economic and environmental impacts of corn, cotton, canola, soybeans, and sugar beets alone have been enormous across the globe. According to economistsBrookes and Barfoot (2020), GE insect-resistant and herbicide-tolerant crops have reduced pesticide spraying by 775.4 million kg. This, in turn, has resulted in a decrease in the use of fuel and tillage, which is equivalent to a reduction of greenhouse gas release on the order of removing 15.27 million cars from the roads.

Improved environmental impacts coincide withsignificant economic benefits to farmersin the form of improved yields (72%) and savings in farming costs (28%) resulting from reduced use of agricultural inputs such as chemicals. Financial gains have exceeded $225 billion since genetically engineered crops first became commercially available, with the most gains realized by farmers in developing countries. Brookes and Barfoot estimate that for every dollar invested in the seeds of GE crops, farmers in developed countries received on average $3.24 extra income. This return on investment increased to $4.41 for farmers in developing countries, where such benefits can be the difference between subsistence farming and being able to sell some of their harvests.

It is unfortunate that a technology that has been so beneficial for so many farmers has been vilified since its beginnings (including, early and often, by reporters, columnists, and commentators in the New York Times), and we wish that Kahns article had put more emphasis on the extant, significant achievements.

The impressive data collected and reported by Brookes and Barfoot are only the beginning. The opportunities for genetically engineered crops to reduce malnutrition and increase farmers profits are endless. Kahn does mention in passingGolden Rice, which produces a precursor of vitamin A and prevents vitamin A deficiencya scourge of children that causes blindness and death in countries where most of their calories come from ricewhich was recentlyapproved for cultivation in the Philippines. (And which has been relentlesslyopposedby activists for decades.) But there are many more such examples, includingstaple engineered cropssuch as rice biofortified withiron,zinc, andfolate.

Besides higher yields and direct economic benefits, the cultivation of insect-resistant and herbicide-tolerant crops also has significant collateral effects in developing countries, such as reducing laborious tasks of women and girls in the field, improved childrens literacy, and greater gender equality. These, in turn, foster improved economic growth and quality of life for communities.

In addition, decreased crop losses due to pests lead not only to improved yields and farmers incomes, but,especially compared to organic farming, also reduce levels of food waste and lower the risk ofcancer,spina bifida in newborns, and other health problems caused by thefungal toxinsaflatoxinandfumonisin, respectively, which are less likely to accumulate in crops that are protected from predation by insects. Improved crop quality and yields and lower agronomic inputs also translate intoless release of greenhouse gases(and, thus, a lower carbon footprint) and less conversion of land to farming.

Unlike the spraying of chemical pesticides, the cultivation of crops like Bt-cotton and Bt-brinjal (eggplant), which contain a protein (from the bacteriumBacillus thuringiensis) toxic to certain insects, does not impactnon-target insects. They are helpful, therefore, for maintaining and restoring the health of natural ecosystems and the sustainable management of wilderness areas. At the same time, genetic engineering technologies related to biomass production using crops ranging fromsugarcanetoswitchgrass, and evenalgae, are helping to produce affordable, attainable energy.

Underscoring their significance, particularly for poor farmers in developing countries, many of these improvements fall under thesustainable development goalsestablished by the United Nations.

PUTTING SCIENCE AND INNOVATION FIRST

It seems that American consumers crave technology in every aspect of their lives except in food production. Why is that? We believe it is the result of a multi-decade, multi-national, multi-billion dollarfear-and-smearcampaign against GE crops and foods by what amounts to an anti-genetic engineering industry.

Technology has helped to double food production in the last 50 years. We have the cheapest, safest, most abundant food supply in history, but now, those seeking to increase the market for organic/natural products, abetted by the woke media, want to force agricultural science to a more primitive, less productive time by embracinginefficient practices. Although they have been successful in creating a niche for their products, we cannot let this way of thinking stymie or reverse the stunning scientific, economic, and environmentaladvancesthat have come from genetic engineering and gene editing technologies, in which the U.S. is preeminent.

Regulators permitting, the next wave of important developments could be in the genetic engineering of animals, in particular the creation of new varieties resistant to devastating, economically crippling diseases. These include pigs resistant to the devastatingPorcine Reproductive and Respiratory Syndrome Virus, the cause of losses to U.S. pig farmers of more than $600 million annually. The foreseeable development of chickens with genetic resistance to avian influenza will be a monumental breakthrough because there is no vaccine against it, and outbreaks result in the culling of tens of millions of birds annually. This field has the potential to create the Next Big Things in agricultureif only innovation were not strangled by unnecessary, misguided government regulation, abetted by an antagonistic media and highly organized, vocal activists.

Americans are experiencing shocking inflation in food prices, and the wider adoption of innovative GE technologies can help to stem it. Insect predation, weeds, and unpredictable weather events are the perennial enemies of farmers but, as discussed above, GE has already made significant strides to mitigate them. The greater exploitation of drought- and flood-resistant crop plants and the prevention of viral diseases in food animals can also aid food production in the parts of the nation plagued by those natural disruptions.

Putting America first means putting science and innovation first.

Billions in potential revenue and life-saving technologies have already been lost to us because of our failure to adopt this attitude. Consider biopharmingthe once-promising biotechnology area that uses genetic engineering techniques to induce crops such as corn, tomatoes ,and tobacco to produce high concentrations of high-value pharmaceuticals (one of which is the Ebola drug, ZMapp). The entire field is moribund because of the Agriculture Departments extraordinary regulatory burdens. And thanks to EPAs policies, which discriminate against organisms modified with the most precise and predictable techniques, the high hopes for genetically engineered biorational microbial pesticides and microorganisms to clean up toxic wastes have evaporated.

As a result, the potential for innovation that modern genetic engineering holds for long-term, robust U.S. economic growth and higher living standards has been drastically reduced. Amazon CEOJeff Bezosalso made this point in the context of developing commercial drones at a conference in 2014. Technology is not going to be the long pole, hesaid. The long pole is going to be regulatory. And yet, regulatory agencies seem to be becoming more imperious and politicized. If U.S. policymakers fail to seize the day, we will likely be overtaken by China, which is fast becoming a significant player. As University of Pennsylvania political scientist Scott Moore haswritten, Chinas progress has implications that span national security, data security, and economic competitiveness.

None of the big picture appeared on Kahn or the New York Timess radar screen. We hope, however, to see a follow-up from her that tells the whole storythat over four decades, genetic engineering has delivered myriad critical economic, health, humanitarian, environmental, and scientific benefits. That we need more of it, regulated more rationally. And that its critics, including her colleagues at the Times, are misinformed and misguided.

Kathleen Hefferon, Ph.D., teaches microbiology at Cornell University. Find Kathleen on Twitter@KHefferon. Henry Miller, a physician and molecular biologist, is a senior fellow at the Pacific Research Institute. He was a Research Associate at the NIH and the founding director of the FDA's Office of Biotechnology. Find Henry on Twitter@henryimiller.

#Reprinted with permission. The original article can be found here.

Read more here:
Is The New York Times Finally 'Learning To Love GMOS'? - American Council on Science and Health

By William A. Haseltine, PhD

When I became an assistant professor at Harvard in the mid-1970s, creating a company was never part of my plan. I had only a dim understanding of how corporations were organized and no understanding of finance. But I was slowly becoming aware of how biotech businesses could be a positive force for health.

I had been keeping tabs as close friends from various universities gave up their tenured positions to join nascent companies gaining an early foothold in the new field of biotechnology. All were racing to apply the new techniques of recombinant DNA (gene splicing) to make new drugs and vaccines. I was beginning to realize that the work I was doing as a research scientist might create a conceptual breakthrough, but the businesses were the ones taking that breakthrough and delivering it in the form of drugs to patients in need.

I was working at the time on retroviruses and their potential role as a cancer-causing agent in animals. Id planned a trip to the West Coast to build up my collection of mouse leukemia viruses, which is where I learned from my friend Richard Lerner, a research chemist at Scripps who had been studying protein structures, that you could accelerate an antibody response by using peptide fragments, as opposed to using whole viruses or virus proteins. I understood the impact of the discovery immediately: using peptide fragments would be a faster, cheaper way to make vaccines.

That was the tipping point. I knew that this knowledge could shorten the time it took to develop new drugs, which at that time required at least ten years and many tens of millions of dollars. I also knew that pets and livestock suffered serious viral infections. If we could test the idea in animals, we wouldnt need to go through the FDA. I could create a company that would be a shortcut to demonstrate that a vaccine can prevent retrovirus infections that cause cancer.

I worked with Deborah Ferris, who had helped get Biogen off the ground, to develop the business plan for a company that would develop animal vaccines with this new technology. I went to every Wall Street banker and venture capitalist I knew, and I eventually landed myself a $5 million commitment. These financiers understood the power of knowledge and the economic benefits it could bring.

I thought, after securing financing, that I had jumped over the hardest and highest hurdle in the process, but I was wrong. I didnt yet realize the political hurdles I still had to jump at Harvard. There was no precedent for a Harvard assistant professor starting a company. Even for full professors, the idea was highly controversial. Harvards president had voiced skepticism, and faculty across the university grumbled, some with outrage, at the notion that biologists or biochemists might turn discoveries developed at Harvard into a personal fortune. This, despite the fact that many of the universitys history and economics professors were making tens of thousands from the sale of their books.

I was faced with many setbacks but managed to overcome them after a bit of luck followed me onto a plane flying from New York to Boston early the next year. I ended up seated beside Larry Fouraker, dean of the Harvard Business School at the time. I pitched him my idea for a company and explained the challenges I was running into at the university. He told me something I had not realized: thanks to the Bayh-Dole Act, which had been passed during a lame-duck session of Congress just months before, universities were now required to create a technology transfer office to turn new ideas into companies.

The laws intent was to promote commercialization of research funded by the federal government. Birch Bayh, Democrat of Indiana, and Bob Dole, Republican of Kansas, were the legislations sponsors in the Senate. Jimmy Carter signed the bill into law. The law states that all universities and research institutes that receive federal funding must file patent applications on all discoveries with practical application and must make best efforts to transfer the technology to businesses for commercial development.

That was my green light. Larry became a close friend and mentor to me. The only requests he ever made of me were to speak to his students at the business school from time to time about entrepreneurship and to pledge some shares of the company I would found, Cambridge BioScience, to the universitys endowment fund. I ended up offering Harvard 5% equity, but they turned it down. They hadnt worked out what they thought the ethics might be of such a transaction. I can assure you that by now they have.

Far from harming my career, creating Cambridge BioScience turned out to be a huge plus. I developed powerful relationships with some of the department chairs and became a role model and adviser to other faculty members in starting their companies. Eventually, Harvards governing board and administration embraced the benefits of professors starting companies, and I was asked to chair a university-wide committee that would clarify the rules governing relationships between professors and the companies they seek to start.

Ironically, the university now requires faculty to pledge a percentage of the founding shares as well as royalties received for startups based on a professors patents. As I noted earlier, Harvard never accepted my 5% offer. But after Cambridge BioScience went public, I sold the 5% and donated the cash. They were happy to accept it.

I learned through the process that our scientific reputation is our capital. I also learned that no person or company ever becomes a success without people like Larry to support and mentor them. This is why I am so pleased to have been invited to contribute to this commemorative, 40th Anniversary edition of GEN. The magazines founder, Mary Ann Leibert, has been a great support to me over many years, but especially at two inflection points in my life.

The first was in the early years of the HIV/AIDS crisis, when I suggested that we create a journal to help cover some of the most exciting, but often neglected, developments in the field. Mary Ann jumped at the idea and took no more than two seconds to agree, and we founded the Journal of AIDS Research and Human Retroviruses.

Fifteen years later, I conceived of the idea of regenerative medicine and began to work with Tony Atala and others to create awareness of the new field and its motto: Regenerative medicine is any medicine designed to restore a person to normal health, including cell and stem cell therapies, gene therapy, tissue engineering, genomic medicine, personalized medicine, biomechanical prosthetics, recombinant proteins, and antibody treatments.

Mary Ann responded immediately and positively once again, offering to create the Society of Regenerative Medicine and another new journal, initiatives that were soon launched. Mary Ann, through her journals, publishing company, and GEN, has always been the wind in the sails of the biotechnology industry.

William A. Haseltine, PhD, is known for his groundbreaking work on HIV/AIDS and the human genome. Haseltine was a professor at Harvard Medical School, where he founded two research departments on cancer and HIV/AIDS. Haseltine is a founder of several biotechnology companies, including Cambridge BioSciences, the Virus Research Institute, ProScript, LeukoSite, Dendreon, Diversa, X-VAX, and Demetrix. He was a founder, chairman, and CEO of Human Genome Sciences, a company that pioneered the application of genomics to drug discovery.

Haseltine is the president of the Haseltine hivFoundation for Science and the Arts and is the founder, chairman, and president of ACCESS Health International, a not-for-profit organization dedicated to improving access to high-quality health worldwide. He was listed by Time Magazine as one of the worlds 25 most influential business people in 2001 and one of the 100 most influential leaders in biotechnology by Scientific American in 2015.

See the original post here:
Making the Transition from an Academic to a Biobusiness Entrepreneur - Genetic Engineering & Biotechnology News